Maximum quantity allowed is 999
请选择数量
CAS RN: 66898-62-2 | 产品编码: T3101
Talniflumate
×
![]()
×
| 产品编码 | T3101 |
| 纯度/分析方法 | >98.0%(HPLC)(N) |
| 分子式/分子量 | C__2__1H__1__3F__3N__2O__4 = 414.34 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 冷藏 (0-10°C) |
| 应避免的情况 | 加热 |
| 包装和容器 | 1G-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 66898-62-2 |
| Reaxys-RN | 503261 |
| PubChem物质ID | 253662062 |
| Merck Index (14) | 9044 |
| MDL编号 | MFCD00866135 |
技术规格
| Appearance | White to Yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Melting point | 166.0 to 170.0 °C |
物性（参考值）
| 熔点 | 168 °C |
| 最大吸收波长 | 287(CHCl3) nm |
GHS
相关法规
| RTECS# | QT2999200 |
运输信息
| HS编码* | 2933.39-000 |
应用
Talniflumate: An Inhibitor of Human Calcium-Activated Chloride Channels
Talniflumate, also known as MSI-1995, is an inhibitor of human calcium-activated chloride channels. It is a prodrug of niflumic acid [T2353]. It was originally developed as an anti-inflammatory agent, but is currently being developed as a mucous regulator for the treatment of cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and asthma. (The product is for research purpose only.)
References
- Pharmacokinetics of talniflumate, a prodrug of niflumic acid, following oral administration to man
- Talniflumate (Genaera) (a review)
- D. Knight, Curr. Opin. Invest. Drugs 2004, 5, 557.
- Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome
- Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate
- Simultaneous determination of niflumic acid and its prodrug, talniflumate in human plasma by high performance liquid chromatography
参考文献
TCIMail
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。